论文部分内容阅读
目的探讨长链非编码RNA LINC00152在结肠癌组织中的原位表达情况及其临床意义。方法用微阵列显著性分析(significance analysis of microarrays,SAM)软件分析下载于NCBI GEO数据库的基因芯片GSE33113数据,筛选结肠癌中差异表达的lncRNA;原位杂交法检测LINC00152在115例结肠癌及其癌旁组织中的表达状况;分析LINC00152阳性率与结肠癌临床病理参数的关系,并用受试者工作曲线(receiver operating characteristics,ROC)评估其作为肿瘤转移、预后预测分子标志物的潜在应用价值。结果 SAM软件分析基因芯片数据发现,结肠癌组织中共有65个lncRNA差异表达(P均<0.01),其中上调lncRNA(倍数变化>2)6个,下调lncRNA(倍数变化<0.5)59个;原位杂交结果显示,LINC00152在结肠癌和癌旁组织中的阳性率分别为63.48%(73/115)和9.57%(11/115),两者差异有统计学意义(χ2=72.091,P<0.05)。临床Ⅰ期、Ⅱ期结肠癌组织中LINC00152的阳性率(27.78%和45.28%)明显低于Ⅲ~Ⅳ期(77.27%),差异有统计学意义(χ2分别为10.234和13.411,P<0.05),发生淋巴结转移的结肠癌组织中LINC00152的阳性率(81.13%)明显高于非淋巴结转移者(48.39%),差异有统计学意义(χ2=13.215,P<0.05)。LINC00152对结肠癌患者淋巴结转移诊断的ROC曲线下面积(AUCROC)为0.771(95%CI:0.588~0.834,P<0.01),当cut off值为3.1时,其敏感性为72.1%、特异性为65.4%、约登指数为0.375。结论LINC00152在结肠癌组织中表达增高,且与临床分期和淋巴结转移有关,可能作为结肠癌转移评估的分子标志物。
Objective To investigate the in situ expression of long-chain non-coding RNA LINC00152 in colon cancer and its clinical significance. Methods Gene chip GSE33113 downloaded from NCBI GEO database was analyzed by SAM (microarray significance analysis) software to screen differentially expressed lncRNA in colon cancer. In situ hybridization was used to detect the expression of LINC00152 in 115 cases of colon cancer and its The relationship between the positive rate of LINC00152 and the clinicopathological parameters of colon cancer was analyzed. The receiver operating characteristics (ROC) was used to evaluate the potential value of LINC00152 as a molecular marker for predicting tumor metastasis and prognosis. Results There was a total of 65 lncRNAs differentially expressed in colon cancer tissues (P <0.01) by SAM software. There were 6 lncRNAs (multiple change> 2) and 59 lncRNAs (multiple change <0.5) The results of hybridization showed that the positive rates of LINC00152 in colon cancer and adjacent normal tissues were 63.48% (73/115) and 9.57% (11/115), respectively, with significant difference (χ2 = 72.091, P <0.05 ). The positive rates of LINC00152 in stage Ⅰ and stage Ⅱ colon cancer tissues were significantly lower than those in stage Ⅲ ~ Ⅳ (77.27%) (χ2 = 10.234 and 13.411, respectively, P <0.05) The positive rate of LINC00152 in colorectal cancer with lymph node metastasis (81.13%) was significantly higher than that in non-lymph node metastasis (48.39%) (χ2 = 13.215, P <0.05). The area under the ROC curve (AUCROC) of LINC00152 for diagnosis of lymph node metastasis in patients with colon cancer was 0.771 (95% CI: 0.588-0.834, P <0.01). When the cut off value was 3.1, the sensitivity was 72.1% 65.4%, the Youden index was 0.375. Conclusion The expression of LINC00152 in colon cancer tissues is increased, and it is correlated with clinical stage and lymph node metastasis. It may be used as a molecular marker for assessing metastasis of colon cancer.